ASLAN Pharmaceuticals Overview

ASLAN Pharmaceuticals Selling, General & Admin

Selling, General & Admin expenses for ASLN.

Quarterly SG&A Expenses

$3.40M

↓ 16.1% YoY

As of Mar 31, 2024

Annual SG&A Expenses (TTM)

$12.59M

↑ 10.49% YoY

Trailing 12 months ending Mar 31, 2024

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin